ArticlePeerJ2025
The concentration of single-stranded DNA-binding proteins is a critical factor in recombinase polymerase amplification (RPA), as revealed by insights from an open-source system.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Point of Care Testing and Recombinase Polymerase Amplification.Journal of clinical laboratory analysis · 2026Article
- Rapid Forensic DNA Profiling via Real-Time Recombinase Polymerase Amplification of InDel Markers.Biosensors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinase polymerase amplification (RPA) facilitates rapid, exponential, isothermal nucleic acid amplification without the need for specialized equipment. Since its development in 2006, RPA has been widely applied to detect hundreds of RNA and DNA targets, spanning point-of-care diagnostics and agricultural uses. However, its reliance on pre-assembled commercial kits limits flexibility for customization. In this study, we introduce an open-source alternative to commercial RPA kits, utilizing purified, heterologously expressed proteins to circumvent the fixed molar ratios of proprietary systems. Our method incorporates enzymes from the bacteriophage T4 homologous recombination pathway-single-stranded binding protein (gp32), recombinase (UvsX), and mediator (UvsY)-along with Moloney murine leukemia virus (MMLV) reverse transcriptase with enhanced thermal stability, and Bst and Bsu DNA polymerases. We assessed the impact of buffer composition, reagent concentrations, and reaction temperature using synthetic SARS-CoV-2 genes. Notably, gp32 concentration and buffer composition emerged as critical factors in optimizing RPA performance. Using this tailored system, we demonstrated successful detection of the SARS-CoV-2 N gene on lateral flow devices (LFDs) with cDNA from eight clinical samples, achieving results consistent with RT-PCR. This open-source RPA platform provides an adaptable and cost-effective alternative for researchers, enabling the exploration of diverse experimental conditions and offering a viable solution for those without access to commercial kits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.